Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DRM006
MIFTS: 61

Dermatitis

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dermatitis

About this section

MalaCards integrated aliases for Dermatitis:

Name: Dermatitis 12 54 43 15 71
Eczema 12 74 29 54 6 42 62 71
Skin Inflammation 12 15
Inflammatory Dermatosis 71

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2723
MeSH 43 D003872
NCIt 49 C2983
UMLS 71 C0011603 C0013595 C3875321
Sources

Summaries for Dermatitis

About this section
MedlinePlus : 42 Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Dermatitis, also known as eczema, is related to allergic contact dermatitis and contact dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Coal tar and Ciclopirox have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A skin disease characterized by itchy, erythematous, vesicular, weeping and crusting patches of skin.

PubMed Health : 62 About eczema: Eczema is a common, chronic, non-infectious skin condition. The main symptom of this inflammatory disease is a very itchy rash. It often affects children. In many cases eczema gets better as the years go by, and it may go away for a while or disappear altogether. Acute flare-ups can really affect quality of life. The itching can be especially bad, making it difficult to concentrate and sleep well. Some people are embarrassed if their rash is visible to others. By taking good care of your skin, using medication and avoiding irritants and other things that can trigger the eczema, it is usually possible to relieve the symptoms at least enough to live a fairly normal life. Eczema is sometimes also called "atopic eczema" or "atopic dermatitis."

Wikipedia : 74 Dermatitis, also known as eczema, is a group of diseases that result in inflammation of the skin. These... more...

Sources

Related Diseases for Dermatitis

About this section

Diseases related to Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1685)
# Related Disease Score Top Affiliating Genes
1 allergic contact dermatitis 35.2 IL5 IL4 IL31 IFNG FLG CCL22
2 contact dermatitis 35.2 IL5 IL4 IL31 IFNG FLG CCL22
3 dermatitis herpetiformis 35.1 IL5 IL4 IL31 CCL11
4 irritant dermatitis 35.1 TSLP IL4 IL31 FLG
5 seborrheic dermatitis 35.1 ZNF750 FLG DSG1 BTD
6 nickel allergic contact dermatitis 34.8 IL5 IL4 IFNG
7 dermatitis, atopic 34.8 TSLP SPINK5 NOD2 KLK7 IL5 IL4
8 dermatitis, atopic, 3 34.7 TSLP FLG
9 eczema herpeticum 34.2 TSLP IL4 IFNG FLG
10 bullous pemphigoid 33.8 IL5 IL4 IL31 IL13 DSG1 CCL11
11 netherton syndrome 33.3 SPINK5 KLK7 FLG DSG1
12 allergic rhinitis 33.2 IL5 IL4 IL13 IFNG CCL11
13 hyper ige syndrome 33.1 STAT3 IL4 IL13 IFNG CCL11
14 celiac disease 1 33.0 NOD2 IL5 IL4 IL13 IFNG
15 milk allergy 33.0 IL5 IL4 IL13
16 onchocerciasis 32.9 IL5 IL4 IL13 DSG1 CCL11
17 egg allergy 32.9 TSLP IL5 IL4 IL13 FLG
18 allergic asthma 32.9 TSLP IL5 IL4 IL13 IFNG CCL11
19 asthma 32.5 TSLP SPINK5 NOD2 IL5 IL4 IL31
20 skin disease 32.4 SPINK5 KLK7 IL5 IL4 IL31 IL13
21 ige responsiveness, atopic 32.4 SPINK5 IL5 IL4 IL13 IFNG
22 urticaria 32.2 IL5 IL4 IL31 IL13
23 food allergy 32.2 SPINK5 IL5 IL4 IL13 IFNG FLG
24 rhinitis 32.1 TSLP IL5 IL4 IL13 IFNG FLG
25 allergic hypersensitivity disease 32.0 TSLP IL5 IL4 IL13 IFNG CCL22
26 psoriasis 32.0 STAT3 NOD2 KLK7 IL5 IL4 IL31
27 cytokine deficiency 31.9 IL5 IL13
28 conjunctivitis 31.9 IL5 IL4 IL13 IFNG CCL11
29 erythema multiforme 31.9 IL5 IL4 IL13 IFNG
30 hypereosinophilic syndrome 31.8 STAT3 IL5 IL4 IL13 IFNG CCL11
31 lichen planus 31.8 IL4 IFNG FLG DSG1
32 folliculitis 31.7 IL5 IL4 IFNG CCL11
33 scabies 31.6 IL31 FLG CCL11
34 mycosis fungoides 31.6 STAT3 IL5 IL4 IFNG CCL22
35 proteasome-associated autoinflammatory syndrome 1 31.6 IL5 IL4 IL13 IFNG CCL11
36 alopecia areata 31.6 IL4 IL13 IFNG FLG
37 cellulitis 31.5 IL5 IL4 IFNG DSG1
38 autoimmune disease 31.5 STAT3 IL5 IL4 IL13 IFNG DSG1
39 cutaneous t cell lymphoma 31.5 STAT3 IL5 IL4 IFNG
40 arthritis 31.4 STAT3 NOD2 IL4 IL13 IFNG
41 respiratory allergy 31.4 TSLP IL5 IL4 IL13 CCL11
42 candidiasis 31.4 STAT3 IL4 IFNG
43 allergic conjunctivitis 31.4 IL5 IL4 IL13 IFNG CCL11
44 neurodermatitis 31.3 IL4 FLG
45 sarcoidosis 1 31.3 NOD2 IL13 IFNG CCL11
46 stevens-johnson syndrome/toxic epidermal necrolysis 31.3 IL5 IL13 IFNG CCL22
47 lichen disease 31.3 IL4 IFNG DSG1
48 mite infestation 31.3 IL5 IL31 FLG
49 bronchitis 31.2 IL5 IL4 IL13 CCL11
50 latex allergy 31.2 IL5 IL4 IL13 FLG

Graphical network of the top 20 diseases related to Dermatitis:



Diseases related to Dermatitis
Sources

Symptoms & Phenotypes for Dermatitis

About this section

UMLS symptoms related to Dermatitis:


pruritus, exanthema

MGI Mouse Phenotypes related to Dermatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 CARD11 CCL11 FAF2 IFNG IL13 IL31RA
2 homeostasis/metabolism MP:0005376 10.07 BTD CARD11 FAF2 IFNG IL13 IL31RA
3 immune system MP:0005387 9.93 CARD11 CCL11 CCL22 IFNG IL13 IL31RA
4 digestive/alimentary MP:0005381 9.91 IFNG IL13 IL4 IL5 NOD2 STAT3
5 integument MP:0010771 9.61 BTD CARD11 DSG1 IFNG IL13 IL4
6 respiratory system MP:0005388 9.23 CARD11 CCL11 IFNG IL13 IL4 IL5
Sources

Drugs & Therapeutics for Dermatitis

About this section

PubMed Health treatment related to Dermatitis: 62

Eczema is a chronic condition. Treatment cannot cure it, but regular skin care and medication can help to keep the itching and rash at bay. The main treatment options are: Basic treatment : Lipid -replenishing and moisturizing products (emollients ) are generously applied to the skin at least twice a day to keep it from drying out. This can help relieve itching and protect the skin from germs and irritants. Special soaps, liquid cleansers and shampoos : Normal soaps and products like shampoo or shower gel contain various substances that can dry out your skin . Special cleansing products without these substances are available to get around this problem. But basic treatment with emollients can usually compensate for the loss of moisture caused by normal soaps. Steroid creams : Eczema flare -ups are usually treated with steroid creams because they can relieve the itching and inflammation . They are typically used only for acute symptoms. But they are sometimes used at regular intervals together with moisturizing skin care products (basic treatment ): for example, as a "weekend treatment" where a steroid cream is applied on one or two days a week. Pimecrolimus and tacrolimus : Pimecrolimus and tacrolimus are two other medicines that can be used to treat eczema . They are not approved for use in children under the age of two years, though. These two medicines are also applied to the skin in a cream or ointment, and can be used if steroid products are not an option. This might be the case if steroid treatment is not tolerated or is ineffective. Pimecrolimus and tacrolimus may also be an option for long-term treatment of sensitive skin in the face and neck area. They can also be used on one or two days per week only, as described above. Other eczema treatment options include wet wraps, UV radiation and medications that suppress certain immune responses. Tablets containing these medicines are used if other treatments don't work, or if the eczema is very severe or affects large areas of skin . Because they have an effect throughout the entire body, they may have more extensive side effects than topical treatments. Allergy medications (antihistamines ) are also commonly used to relieve itching . But research has now shown that they are not suitable for treating eczema , whether used as tablets or a cream. People often try out herbal products or dietary supplements, such as evening primrose oil , borage oil, vitamin B6, vitamin E and zinc . But research hasn't shown that these products are effective. Many other treatments such as laser therapies or hyposensitization have not yet been studied enough, so they are not recommended by medical associations.

Drugs for Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 572)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Coal tar Approved Phase 4 8007-45-2
2
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
3
Titanium dioxide Approved Phase 4 13463-67-7
4
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
5
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
6
Levocetirizine Approved Phase 4 130018-77-8 1549000
7
Desoximetasone Approved Phase 4 382-67-2 5311067
8
Glycerol Approved, Investigational Phase 4 56-81-5 753
9
carbamide peroxide Approved Phase 4 124-43-6
10
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
11
Montelukast Approved Phase 4 158966-92-8 5281040
12
Menthol Approved Phase 4 2216-51-5 16666
13
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
16 Brodalumab Approved, Investigational Phase 4 1174395-19-7
17
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
18
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
19
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
20
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
21
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
22
Omalizumab Approved, Investigational Phase 4 242138-07-4
23
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
24
Abatacept Approved Phase 4 332348-12-6 10237
25
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
26
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
27
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
28
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
29
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
30 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
31
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
32
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8
33
Ustekinumab Approved, Investigational Phase 4 815610-63-0
34
Allantoin Approved Phase 4 97-59-6 204
35
Vancomycin Approved Phase 4 1404-90-6 14969 441141
36
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
37
Chromium Approved Phase 4 7440-47-3 27668
38 Vedolizumab Approved Phase 4 943609-66-3
39
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
40
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
41
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
42
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
43
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
44
Alitretinoin Approved, Investigational Phase 4 5300-03-8 449171 444795
45
leucovorin Approved Phase 4 58-05-9 6006 143
46
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
47
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
48
Dapsone Approved, Investigational Phase 4 80-08-0 2955
49
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
50
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985

Interventional clinical trials:

(show top 50) (show all 1625)
# Name Status NCT ID Phase Drugs
1 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
2 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
3 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
4 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
5 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
6 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
7 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
8 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
9 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
10 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
11 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
12 Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit Unknown status NCT02032394 Phase 4 Povidone-iodine;Chlorhexidine;Normal saline
13 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
14 The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers: A Randomized Controlled Trial. Unknown status NCT03021161 Phase 4 Probiotic Formula
15 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
16 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
17 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
18 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
19 Randomized, Double Blind, Controlled Trial on Effectiveness Combined Probiotics in the Treatment of Atopic Dermatitis in Children up to 6 Months Completed NCT02519556 Phase 4 Probiatop;Placebo
20 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A
21 A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
22 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
23 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
24 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
25 A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment Completed NCT00673725 Phase 4 Locobase® REPAIR
26 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
27 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
28 An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
29 Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods Completed NCT00180141 Phase 4 Elidel-Creme
30 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
31 A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis Completed NCT00510003 Phase 4 Pimecrolimus
32 A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
33 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
34 Non-comparative Open-label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion Completed NCT00925730 Phase 4 Pimecrolimus
35 A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
36 Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
37 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
38 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo
39 A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents Completed NCT00568412 Phase 4 Elidel
40 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
41 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
42 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
43 Short Term Growth in Children With Atopic Dermatitis Completed NCT00236106 Phase 4 tacrolimus ointment 0.1%;mometasone furoate 0.1%
44 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
45 Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study Completed NCT02589392 Phase 4
46 An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population Completed NCT01137032 Phase 4 Pandel Cream 0.1%
47 Quality of Life Study in Adults With Facial Eczema Completed NCT00120302 Phase 4 Pimecrolimus;Placebo
48 Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis Completed NCT00819507 Phase 4 Fluocinonide
49 Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study) Completed NCT00878670 Phase 4 EPOGAM 1000
50 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo

Search NIH Clinical Center for Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alclometasone
alclometasone dipropionate
amcinonide
Clobetasol
Clobetasol Propionate
cocoa butter
Cod Liver Oil
Colloidal oatmeal
eucerin
EUCERITE
Glycerin
GLYCERIN LIQUID
GLYCERIN,ANHYDROUS
GLYCERIN,DEHYDRATED
Lactic acid
LACTIC ACID LIQUID
LACTIC ACID,BUFFERED
methdilazine
Methdilazine hydrochloride
OATMEAL 1 g in 1 g TOPICAL POWDER [Soothing Bath Treatment]
Racemethionine
retinol acetate
retinyl palmitate
Vitamin A
VITAMIN A (AS ACETATE & BETA CAROTENE)
VITAMIN A (AS PALMITATE & BETA CAROTENE)
VITAMIN A (NATURAL)
VITAMIN A PALMITATE (SOLUBILIZED)
Zinc Oxide

Cochrane evidence based reviews: dermatitis

Sources

Genetic Tests for Dermatitis

About this section

Genetic tests related to Dermatitis:

# Genetic test Affiliating Genes
1 Eczema 29
Sources

Anatomical Context for Dermatitis

About this section

MalaCards organs/tissues related to Dermatitis:

40
Skin, Testes, T Cells, Breast, Colon, Neutrophil, Eye
Sources

Publications for Dermatitis

About this section

Articles related to Dermatitis:

(show top 50) (show all 44110)
# Title Authors PMID Year
1
Effects of gut microbiome and environment on the development of eczema in Chinese infants. 42 61
32481318 2020
2
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. 42 61
32087126 2020
3
Emollients for prevention of atopic dermatitis in infancy. 61 42
32087123 2020
4
Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. 61 54
20199415 2010
5
Melatonin inhibits the development of 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. 54 61
19817972 2009
6
Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. 54 61
19706451 2009
7
Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. 61 54
19541355 2009
8
[Relationship between gene polymorphism of CYP2E1, CYP1A1, IL-4 and medicamentosa-like dermatitis induced by trichloroethylene]. 54 61
19351467 2009
9
Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. 54 61
18795918 2009
10
Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. 61 54
18249437 2008
11
A study of allergen-specific IgE antibodies in Indian patients of atopic dermatitis. 61 54
18388364 2008
12
A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. 61 54
17900679 2007
13
IgE values and T-lymphocyte subsets in children with atopic eczema/dermatitis syndrome. 61 54
18034970 2007
14
A novel atopic dermatitis model induced by topical application with dermatophagoides farinae extract in NC/Nga mice. 61 54
17460441 2007
15
Exocytosis of Neutrophil Formyl peptide receptor-like 1 (fPRL1) results in downregulation of cytoplasmic fPRL1 in patients with purulent dermatitis. 54 61
17460114 2007
16
A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. 61 54
17346444 2007
17
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. 54 61
17030248 2006
18
CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14 IL-4 transgenic mouse model. 54 61
16735375 2006
19
Comparison of fecal microflora in children with atopic eczema/dermatitis syndrome according to IgE sensitization to food. 54 61
16618364 2006
20
IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. 54 61
16461143 2006
21
WBN/Kob-Ht rats spontaneously develop dermatitis under conventional conditions: another possible model for atopic dermatitis. 61 54
16365525 2005
22
Candida albicans-specific lymphoproliferative and cytokine (IL-4 and IFN-gamma) responses in atopic eczema dermatitis syndrome. Evidence of CD4/CD8 and CD3/CD16+CD56 ratio elevations in vitro. 54 61
15946244 2005
23
Direct injection of plasmid DNA into the skin induces dermatitis by activation of monocytes through toll-like receptor 9. 54 61
15655803 2005
24
Characterization of spontaneous dermatitis in beige rats with IgE hyperproduction. 54 61
15591815 2005
25
Vital role of the itch-scratch response in development of spontaneous dermatitis in NC/Nga mice. 61 54
15327540 2004
26
Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation. 54 61
15186319 2004
27
Cloning, expression and characterization of two new IgE-binding proteins from the yeast Malassezia sympodialis with sequence similarities to heat shock proteins and manganese superoxide dismutase. 61 54
15128298 2004
28
Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. 54 61
15131578 2004
29
Ciliary neurotrophic factor preferentially enhances spontaneous IgE production by B cells from atopic patients. 54 61
15223271 2004
30
Association between the occurrence of the anticardiolipin IgM and mite allergen-specific IgE antibodies in children with extrinsic type of atopic eczema/dermatitis syndrome. 61 54
14763929 2004
31
IgE-binding components of cultured human keratinocytes in atopic eczema/dermatitis syndrome and their crossreactivity with Malassezia furfur. 54 61
14763930 2004
32
Exposure to road traffic enhances allergic skin wheal responses and increases plasma neuropeptides and neurotrophins in patients with atopic eczema/dermatitis syndrome. 61 54
14762973 2004
33
Suckling reduces allergic skin responses and plasma levels of neuropeptide and neurotrophin in lactating women with atopic eczema/dermatitis syndrome. 54 61
14707470 2003
34
Quantification of IgE antibodies simplifies the classification of allergic diseases in 4-year-old children. A report from the prospective birth cohort study--BAMSE. 54 61
14675470 2003
35
Dendritic cells and atopic eczema/dermatitis syndrome. 61 54
14501434 2003
36
Enhancement of allergic skin wheal responses in patients with atopic eczema/dermatitis syndrome by playing video games or by a frequently ringing mobile phone. 61 54
12795649 2003
37
Atopy patch test reactions to Malassezia allergens differentiate subgroups of atopic dermatitis patients. 54 61
12653739 2003
38
Hochu-ekki-to suppresses development of dermatitis and elevation of serum IgE level in NC/Nga mice. 61 54
12951838 2003
39
HLA-DR-dependent increased mannan-induced lymphoproliferative response in atopic eczema dermatitis syndrome. 54 61
12580811 2003
40
Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. 54 61
12584051 2003
41
Enhanced release of platelet factor 4 into the circulation in patients with atopic eczema/dermatitis syndrome. 54 61
14737958 2003
42
Characterization of monocyte subtypes in the allergic form of atopic eczema/dermatitis syndrome. 61 54
12269940 2002
43
A reducing microenvironment leads to the generation of FcepsilonRIhigh inflammatory dendritic epidermal cells (IDEC). 54 61
12406329 2002
44
Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel serological marker of disease activity. 54 61
12169178 2002
45
Autoimmune progesterone dermatitis manifested as erythema annulare centrifugum: Confirmation of progesterone sensitivity by in vitro interferon-gamma release. 61 54
12140482 2002
46
Peripheral blood mononuclear cells from IgE- and non-IgE-associated allergic atopic eczema/dermatitis syndrome (AEDS) demonstrate increased capacity of generating interleukin-13 but differ in their potential of synthesizing interferon-gamma. 54 61
11972483 2002
47
Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitis. 61 54
11751999 2002
48
Improvement of skin symptoms and mineral imbalance by drinking deep sea water in patients with atopic eczema/dermatitis syndrome (AEDS). 54 61
12325458 2002
49
[Induction of atopic dermatitis-like skin lesion in NC/Nga mice--the influence of the skin barrier destroying solution to the induction of dermatitis]. 54 61
11830999 2001
50
Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/Nga. 54 61
11490156 2001
Sources

Variations for Dermatitis

About this section
Sources

Expression for Dermatitis

About this section
Search GEO for disease gene expression data for Dermatitis.
Sources

Pathways for Dermatitis

About this section

Pathways related to Dermatitis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.95 STAT3 NOD2 IL5 IL4 IL31RA IL31
2
PEDF Induced Signaling 63
Show member pathways
 13.61 TSLP STAT3 IL5 IL4 IL31RA IL31
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.18 STAT3 NOD2 IL5 IL4 IL31RA IL31
4
Allograft rejection 1 36
Show member pathways
 12.75 IL5 IL4 IL13 IFNG CCL11
5
Pathways in cancer 36
12.74 STAT3 IL5 IL4 IL13 IFNG
6
Th17 cell differentiation 36
Show member pathways
 12.53 STAT3 NOD2 IL5 IL4 IL13 IFNG
7
T cell receptor signaling pathway 36
Show member pathways
 12.52 STAT3 IL5 IL4 IFNG CARD11
8
JAK-STAT signaling pathway 36
Show member pathways
 12.4 TSLP STAT3 IL5 IL4 IL13 IFNG
9
IL-17 Family Signaling Pathways 64
Show member pathways
 12.22 STAT3 IL5 IL4 IL13 IFNG CCL11
10
Interleukin-4 and 13 signaling 65
11.89 STAT3 IL4 IL13 CCL22 CCL11
11
Th17 Differentiation 64
Show member pathways
 11.76 STAT3 IL4 IFNG
12
Glucocorticoid receptor regulatory network 1
11.75 IL5 IL4 IL13 IFNG
13
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.66 IL5 IL4 IFNG
14
Lung fibrosis 1
11.6 IL5 IL4 IL13 CCL11
15
IL4-mediated signaling events 1
11.57 IL5 IL4 CCL11
16
Innate Lymphoid Cells Differentiation 64
11.46 TSLP IL5 IL4 IL13 IFNG
17
Interleukin-10 signaling 65
11.45 STAT3 IL4 IL13 CCL22
18
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.44 TSLP STAT3 CCL11
19
Inflammatory Response Pathway 1
11.27 IL5 IL4 IFNG
20
IL12 signaling mediated by STAT4 1
11.18 STAT3 IL13 IFNG
21
Cytokines and Inflammatory Response 1
11.09 IL5 IL4 IL13 IFNG
22
OX40 Pathway 63
10.97 IL5 IL4 IL13 IFNG
23
G-protein signaling_Rap2B regulation pathway 22
10.93 IL5 IL4 IL13 CCL22 CCL11
24
Development and heterogeneity of the ILC family 1
10.86 TSLP IL5 IL4 IL13 IFNG
25
Th2 Differentiation 64
10.83 IL5 IL4 IL31 IL13 IFNG CCL22
26
IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
10.73 IL5 IL4 IL13
Sources

GO Terms for Dermatitis

About this section

Cellular components related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 TSLP KLK7 IL5 IL4 IL31 IL13
2 extracellular region GO:0005576 9.4 TSLP SPINK5 KLK7 IL5 IL4 IL31
3 epidermal lamellar body GO:0097209 9.16 SPINK5 KLK7

Biological processes related to Dermatitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.92 STAT3 IL5 IL13 CCL22 CCL11
2 immune response GO:0006955 9.85 IL5 IL4 IL13 IFNG CCL22 CCL11
3 positive regulation of cell proliferation GO:0008284 9.8 TSLP STAT3 NOD2 IL5 IL4 IL31RA
4 response to virus GO:0009615 9.79 IFNG CCL22 CCL11
5 regulation of T cell differentiation GO:0045580 9.61 SPINK5 CARD11
6 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.61 NOD2 IFNG
7 JAK-STAT cascade GO:0007259 9.61 STAT3 IL31RA IFNG
8 positive regulation of ATP biosynthetic process GO:2001171 9.6 STAT3 IL4
9 positive regulation of chemokine biosynthetic process GO:0045080 9.59 IL4 IFNG
10 negative regulation of macrophage activation GO:0043031 9.58 IL4 IL31RA
11 macrophage activation GO:0042116 9.58 IL4 IL13
12 microglial cell activation GO:0001774 9.58 IL4 IL13 IFNG
13 positive regulation of interleukin-10 secretion GO:2001181 9.57 IL4 IL13
14 positive regulation of mast cell degranulation GO:0043306 9.56 IL4 IL13
15 cytokine-mediated signaling pathway GO:0019221 9.56 STAT3 IL5 IL4 IL31RA IL31 IL13
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.55 IL4 IFNG
17 positive regulation of interleukin-13 production GO:0032736 9.54 TSLP IL4
18 positive regulation of cellular respiration GO:1901857 9.51 IL4 IFNG
19 positive regulation of interleukin-10 production GO:0032733 9.5 TSLP NOD2 IL4
20 neuroinflammatory response GO:0150076 9.49 IL4 IFNG
21 T-helper 2 cell cytokine production GO:0035745 9.48 IL4 IL31RA
22 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
23 positive regulation of B cell proliferation GO:0030890 9.46 IL5 IL4 IL13 CARD11
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.1 TSLP STAT3 IL4 IL31RA IL13 IFNG

Molecular functions related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TSLP IL5 IL4 IL31 IL13 IFNG
2 CARD domain binding GO:0050700 9.16 NOD2 CARD11
3 cytokine receptor binding GO:0005126 9.13 IL4 IL31 IL13
Sources

Sources for Dermatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....